small molecule

CYCLOSPORINE

CYCLOSPORINE

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameCYCLOSPORINE
Active ingredientCYCLOSPORINE
Strength0.05%
Dosage formEMULSION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalNovember 2025
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.